Bristol-Myers Squibb Company (BMY) Balance Sheet

The sequential decline in debt, particularly the $3.3B reduction in 2026Q2, suggests management is prioritizing balance sheet repair over aggressive capital deployment. This deleveraging, combined with a rising equity base from $16.5B to $22.3B, points to improving financial flexibility, though the pace may slow as cash is also used for dividends and M&A.

The reduction in absolute debt and D/E ratio suggests a strategic shift toward a more conservative capital structure, likely to mitigate refinancing risk in a higher-rate environment. However, with debt still representing nearly half of total assets, interest expense will continue to pressure earnings, and the company's ability to service this debt depends on stable cash flows from key products like Eliquis and Opdivo.

The stability of goodwill over the period suggests no impairment charges have been taken, but the risk remains if growth assets underperform. The modest PPE relative to total assets indicates a low capital intensity, consistent with a pharma business that outsources manufacturing. Investors should monitor goodwill for potential write-downs if pipeline setbacks occur.

The growth in retained earnings, despite ongoing dividend payments, suggests that net income is increasingly being retained to bolster equity. This trend, coupled with a lower D/E, enhances the company's ability to absorb shocks and invest in growth initiatives. However, the pace of equity accumulation may slow if the patent cliff accelerates revenue declines.

The improvement in the current ratio reflects both higher cash balances and a reduction in current liabilities, likely due to debt repayments. This provides a cushion against near-term uncertainties, including potential revenue dips from patent expirations. However, the absolute cash level is modest relative to total debt, so liquidity remains dependent on continued operating cash flow generation.